CD8A and cancer: The ultrasmall particle size and extended pharmacokinetics facilitated the intratumoral penetration of sHDL-DOX, which then triggered the ICD of cancer cells for the initiation of the immunologic cascade (Figure 4D), leading to an upregulated “eat me” signal and enhanced potent responses of CD8+ T cells (IFN-γ + CD8+ and AH1-specific CD8+ T cells) (Figure 4E,F).